Pharmaceuticals News and Research

RSS

Thomson Reuters, Linguamatics launch Cortellis Informatics Clinical Text Analytics for I2E

The Intellectual Property & Science business of Thomson Reuters, the world leader in intelligent information for businesses and professionals, today announced a collaboration with Linguamatics to advance pharmaceutical clinical trial research and development (R&D) with the launch of Cortellis Informatics Clinical Text Analytics for I2E.

4 Dec 2014

BeyondSpring Pharmaceuticals plans to initiate Plinabulin Phase 3 pivotal trial in NSCLC patients

BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it plans to initiate a Phase 3 pivotal trial of lead product candidate, Plinabulin, in patients with non-small cell lung cancer (NSCLC) in the first quarter of 2015.

4 Dec 2014

New collaborative project aims to generate 3% productivity boost at Australian pharmaceutical sites

META, a collaborative network of high potential manufacturing businesses and researchers, has today announced a collaborative project between Hospira, GlaxoSmithKline and CSL to generate a targeted 3% productivity boost with an estimated return on investment of up to $2.4M dollars at Australian pharmaceutical sites.

4 Dec 2014

BTG agrees to acquire PneumRx for $475 million

PneumRx, Inc., a leader in the field of interventional pulmonology, today announced that it has signed an agreement to be acquired by BTG Plc in a deal worth up to $475 million, based on an initial consideration of $230 million and up to $245 million in performance-related milestone payments.

4 Dec 2014

CytRx's clinical trials for aldoxorubicin placed on partial clinical hold

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the Company has received written notice from the United States Food and Drug Administration that its clinical trials for aldoxorubicin have been placed on partial clinical hold.

3 Dec 2014

Vital Therapies to use Veeva Vault applications to share clinical information

With an investigational combination biological product in Phase III clinical trials and a recent IPO, Vital Therapies, Inc. is readying its clinical and regulatory operations for global collaboration and greater efficiency with cloud-based Veeva Vault eTMF and Veeva Vault Submissions content management applications from Veeva Systems.

3 Dec 2014

Physical activity linked to children's brain and cognitive development, scholastic achievement

Over the past thirty years, physical activity among children has declined markedly. The public health implications of this decline include a growing prevalence of obesity and chronic diseases such as diabetes and hypertension. A new issue of Monographs of the Society for Research in Child Development expands the focus to ask whether physical activity is also related to children's brain and cognitive development and achievement in school.

3 Dec 2014

Monash University, 60P Australia partner to develop Fenretinide drug for dengue fever

Monash University and 60P Australia Pty Ltd, a subsidiary of 60° Pharmaceuticals LLC, have announced today an exclusive partnering deal, with 60P obtaining rights to develop the drug Fenretinide for dengue fever.

2 Dec 2014

AcelRx Pharmaceuticals' Zalviso device gets CE Mark approval

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has received CE Mark approval (Conformite Europeenne) for the Zalviso device.

2 Dec 2014

InnaVirVax receives DSMB recommendation to pursue VAC-3S Phase 2 study in HIV

InnaVirVax, a biopharmaceutical company specialized in research and development on therapeutic and diagnostic solutions for diseases linked to immune dysregulation, today announces the recommendation of its independent Data Safety and Monitoring Board (DSMB) to pursue the Phase 2 study (IPROTECT1) of VAC-3S according to the planned protocol.

2 Dec 2014

Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock

Apellis Pharmaceuticals, Inc., a leading biotechnology company applying immunotherapy to autoimmune disease, today announced that it has completed a $33M private placement of its Series C Preferred Stock.

2 Dec 2014

New FDA data shows disparities still exist in medical research

The U.S. Food and Drug Administration (FDA) released data today on a dedicated website from six studies reflecting a two-month period in response to a requirement under the "FDA Action Plan to Enhance the Collection and Availability of Demographic Subgroup Data" to make transparent the percentage of female and minority participation in clinical trials for medications intended for all populations.

2 Dec 2014

Researchers explore how to turn on the activity of paternal gene

Most genes are inherited as two working copies, one from the mother and one from the father. However, in a few instances, a gene is imprinted, which means that one copy is silenced. This is called genomic imprinting. If the active copy is mutated, then disease results, even though the silenced gene copy may be normal.

2 Dec 2014

Global stem cell market estimated to reach US$117.66B in 2018

Stem cells have the potential to transform healthcare by enabling the cost-effective treatment of many conditions that currently have poor treatment options.

2 Dec 2014

Otsuka Pharmaceutical to acquire Avanir Pharmaceuticals for $3.5B

Avanir Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement with Otsuka Pharmaceutical Co., Ltd. pursuant to which Otsuka will acquire Avanir for $17.00 per share in cash.

2 Dec 2014

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Novartis will highlight more than 250 abstracts demonstrating advances in blood and breast cancer research at the upcoming American Society of Hematology (ASH) annual meeting December 6-9, and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) December 9-13.

2 Dec 2014

Commonly used osteoporosis medications may also prevent lung, breast and colon cancers

The most commonly used medications for osteoporosis worldwide, bisphosphonates, may also prevent certain kinds of lung, breast and colon cancers, according to two studies led by researchers at the Icahn School of Medicine at Mount Sinai and published today in the Proceedings of the National Academy of Sciences.

2 Dec 2014

Component of Glycyrrhiza uralensis plant may thwart development of metabolic disorders

New research published in the December 2014 issue of the Journal of Leukocyte Biology, shows that a component found in in the plant, Glycyrrhiza uralensis, may inhibit the development of metabolic disorders by stopping the activation of NLRP3, a protein involved in the disease process.

2 Dec 2014

Sanford-Burnham, Mayo Clinic scientists to jointly find new treatment for resistant hypertension

Sanford-Burnham Medical Research Institute at Lake Nona and Mayo Clinic today announced that a joint team of scientists has been selected as a winner of GlaxoSmithKline's 2014 Discovery Fast Track Challenge.

2 Dec 2014

Mylan, CAS to raise funds and awareness for people living with HIV/AIDS

Mylan Inc. and the Canadian AIDS Society (CAS) today announced a joint initiative to raise funds and awareness for Canadians and people worldwide who are living with or at risk of HIV/AIDS.

2 Dec 2014

Pharmaceuticals News and Research

Thomson Reuters, Linguamatics launch Cortellis Informatics Clinical Text Analytics for I2E

BeyondSpring Pharmaceuticals plans to initiate Plinabulin Phase 3 pivotal trial in NSCLC patients

New collaborative project aims to generate 3% productivity boost at Australian pharmaceutical sites

BTG agrees to acquire PneumRx for $475 million

CytRx's clinical trials for aldoxorubicin placed on partial clinical hold

Vital Therapies to use Veeva Vault applications to share clinical information

Physical activity linked to children's brain and cognitive development, scholastic achievement

Monash University, 60P Australia partner to develop Fenretinide drug for dengue fever

AcelRx Pharmaceuticals' Zalviso device gets CE Mark approval

InnaVirVax receives DSMB recommendation to pursue VAC-3S Phase 2 study in HIV

Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock

New FDA data shows disparities still exist in medical research

Researchers explore how to turn on the activity of paternal gene

Global stem cell market estimated to reach US$117.66B in 2018

Otsuka Pharmaceutical to acquire Avanir Pharmaceuticals for $3.5B

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Commonly used osteoporosis medications may also prevent lung, breast and colon cancers

Component of Glycyrrhiza uralensis plant may thwart development of metabolic disorders

Sanford-Burnham, Mayo Clinic scientists to jointly find new treatment for resistant hypertension

Mylan, CAS to raise funds and awareness for people living with HIV/AIDS

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence